(Gimeracil + oteracil + tegafur) is under clinical development by Taiho Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Gimeracil + oteracil + tegafur)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Gimeracil + oteracil + tegafur) overview

Gimeracil, Oteracil, Tegafur (Teysuno/TS-1) is a fixed dose combination acts as an anti-metabolite preparation. It is formulated as hard gelatin capsules and granules for oral route of administration. It is indicated in adults for the treatment of advanced gastric cancer, biliary cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer, when given in combination with cisplatin. TS-1 is under development for the treatment of metastatic pancreatic cancer and resected adenocarcinoma pancreatic cancer.

It was also under development for the treatment of non-small cell lung cancer, hepatocellular carcinoma, uterocervicall cancer and renal cell carcinoma, pancreatic ductal adenocarcinoma and colorectal cancer (as an adjuvant therapy).

Taiho Pharmaceutical overview

Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, allergy, immunology and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.

For a complete picture of (Gimeracil + oteracil + tegafur)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.